Ardent Health Partners Q4 2024 Earnings Report

Ardent Health Partners EPS Results

• Actual EPS: $0.81
• Consensus EPS: $0.50
• Beat/Miss: Beat by +$0.31
• One Year Ago EPS: N/A

Ardent Health Partners Revenue Results

• Actual Revenue: $1.61 billion
• Expected Revenue: $1.48 billion
• Beat/Miss: Beat by +$122.23 million
• YoY Revenue Growth: N/A

Ardent Health Partners Announcement Details

• Quarter: Q4 2024
• Date: 2/26/2025
• Time: After Market Closes
• Conference Call Date: Thursday, February 27, 2025
• Conference Call Time: 9:00AM ET

Ardent Health Partners (NYSE:ARDT), Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

Ardent Health Partners Q4 2024 Earnings Call Transcript

Presentation

[Operator]

Good morning. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ardent Health Partners Fourth Quarter twenty twenty four Earnings Conference Call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise.

[Operator]

After the speakers' remarks, there will be a question and answer session. At this time, I would like to turn the conference over to Dave Cyglow, Senior Vice President of Investor Relations.

[David Styblo, SVP - Investor Relations at Ardent Health Partners]

Thank you, operator, and welcome to Ardent Health's fourth quarter twenty twenty four results conference call. Joining me today is Ardent's President and Chief Executive Officer, Marty Bonnick and Chief Financial Officer, Alfred Lumphaine. Marty and Alfred will provide prepared remarks and then we will open the line to questions. Before I turn the call over to Marty, I want to remind everyone that today's discussion contains forward looking statements about future business and financial expectations. Actual results may differ significantly from those projected in today's forward looking statements due to various risks and uncertainties, including the risks described in our periodic reports filed with the SEC.

[David Styblo, SVP - Investor Relations at Ardent Health Partners]

Except as required by law, we undertake no obligation to update our forward looking statements. Further, this call will include the discussion of certain non GAAP financial measures, including adjusted EBITDA and adjusted EBITDAR. Reconciliation of these measures to the closest GAAP financial measure is included in our quarterly earnings press release, which was issued yesterday evening after the market closed and is available at ardenhealth.com. With that, I'll turn the call over to Marty.

[Marty Bonick, CEO at Ardent Health Partners]

Thank you, Dave, and good morning. We appreciate everyone joining on the call and webcast. 2024 was a transformational year for Ardent as we demonstrated strong growth and agility in advancing our strategic objectives while executing upon a number of important milestones along the way. Our mission of caring for people resulted in Arden serving over 1,200,000 unique individuals across our eight markets, adding services and facilities to make healthcare easier for patients to access and receive care. Last July, we also completed our IPO, strengthening our financial position to drive continued growth and innovation.

[Marty Bonick, CEO at Ardent Health Partners]

Today, I'm excited to share several positive updates about the company and its performance. I will provide a comprehensive summary of our fourth quarter and full year financial results, highlight key strategic updates and discuss our outlook for 2025. As we embark on a new year, I want to emphasize that Arden remains steadfast in its commitment to delivering exceptional quality and service to our patients while ensuring sustainable long term value for our shareholders. Our strategic framework of market share growth in both inpatient and outpatient services, margin expansion and disciplined capital deployment. Delivering against our financial goals and building a track record of performance is paramount to the Arden management team.

[Marty Bonick, CEO at Ardent Health Partners]

To that end, we had a very strong finish to 2024 and have several positive financial and operating items to discuss. To start at a high level, we reported robust fourth quarter results punctuated by year over year revenue growth of 19% and adjusted EBITDA growth of over 200%. For the full year 2024, we grew revenue 10%, increased adjusted EBITDA 58% and expanded EBITDAR margins two forty basis points to 12.5%. This marks a great year and is testament to the hard work the Arden team has put in to execute on our strategic priorities. During 2024, we made considerable progress on our service line optimization initiatives, which expanded capacity to engage in higher acuity procedures.

[Marty Bonick, CEO at Ardent Health Partners]

We meaningfully enhanced supply chain efficiencies. We used AI to improve clinical performance with virtual nursing and advanced bedside monitoring technology, reducing mortality and improving length of stay as well as operationally in optimizing operating room schedules to drive strategic surgical growth. And we advanced our ambulatory growth strategy, highlighted by the recent acquisition of Nexcare Urgent Cares in Oklahoma and New Mexico. This brings a total of 27 new urgent care centers into the Ardent network in the last year, which should lead to increased volumes over time. We are also pleased that CMS retroactively approved the New Mexico State Directed Payment Program in November for the period covering the second half of twenty twenty four.

[Marty Bonick, CEO at Ardent Health Partners]

This approval was a key milestone for the state as it will greatly support the broader provider community's ability to serve Medicaid patients in New Mexico with access to high quality care. And I'm proud of the work our team did in collaborating with and supporting the state to help bring the DPP program to fruition. In connection with the New Mexico DPP approval, we recorded revenues of $94,000,000 and EBITDA of $65,000,000 in the fourth quarter of twenty twenty four to reflect the retroactive financial impact for both the third and fourth quarters. This retroactive benefit was not in our 2024 guidance, and accordingly, the company significantly exceeded revenue and EBITDA guidance for 2024. When we exclude these amounts from the reported results, the company delivered financial and operating performance that was either consistent with or favorable to our 2024 guidance, which we raised in November in conjunction with the third quarter results.

[Marty Bonick, CEO at Ardent Health Partners]

More specifically, excluding the impact of the New Mexico DPP program, 2024 revenue finished near the top end of guidance, while net patient service revenue per adjusted admission growth was above the top end of the guidance range. Meanwhile, adjusted admission growth and adjusted EBITDA were both modestly above the 2024 guidance midpoints. These are all signs of the underlying strength of our business and the results demonstrate our ability to deliver on our financial projections. Ardent's balance sheet also continues to strengthen. During the last quarter's earnings call, we indicated that a lease adjusted net leverage ratio would approach three times at the year end compared to the 3.5 times we reported in the third quarter.

[Marty Bonick, CEO at Ardent Health Partners]

We delivered on that and finished the year at 2.9 times at December 31. We have over $550,000,000 of cash on hand and available liquidity of $845,000,000 Collectively, this allows Arden to operate from a position of strength, particularly as we assess both inorganic and organic growth opportunities. On that front, we're pleased to announce that in early January, the acquisition of 18 urgent care clinics crossed New Mexico and Oklahoma from NexCare Urgent Care. This acquisition significantly expands Arden's ambulatory operations in both markets and complements our existing health service access points beyond the main urban area. Prior to the transaction, we had only one urgent care facility across Tulsa and Albuquerque.

[Marty Bonick, CEO at Ardent Health Partners]

Post acquisition, we will have meaningful share of the urgent care market in each of those geographies. These are attractive assets with adjusted EBITDA margins in the mid teens. This acquisition fits squarely within our strategic growth initiatives, which include the build out of our ambulatory footprint, either via M and A or de novo development around our existing hospitals. Patients are increasingly using urgent care as an access point when there is a backlog at their local primary care office or when they do not have primary care providers. It is becoming our first interaction with many patients, thereby bringing new patients into our system.

[Marty Bonick, CEO at Ardent Health Partners]

Importantly, we see strategic value in owning urgent care facilities in two ways. First, we reap the economic benefit of owning these higher margin assets on a standalone basis. And second, it creates a downstream benefit and incrementally increases volumes at our existing hospitals and clinics. As a proof point to the downstream volume benefit, we saw that 45% of the twenty twenty four patient visits in the six urgent care centers we acquired in East Texas were new to the ARDAN system. Furthermore, of those new visits, approximately fifteen percent resulted in additional care within thirty days.

[Marty Bonick, CEO at Ardent Health Partners]

Going forward, we are looking to replicate this type of success as we integrate the NexCare assets. The broader M and A pipeline remains active and we will continue to evaluate outpatient as well as inpatient opportunities. We will remain financially disciplined both in terms of purchase price and our overall leverage. And we will seek assets where we can deliver synergies and demonstrate accretion over a two to three year horizon. We will also explore joint venture opportunities as part of our inpatient M and A growth strategy as that model has provided ardent differentiated value.

[Marty Bonick, CEO at Ardent Health Partners]

As we turn to 2025, we are optimistic and expect to deliver another strong year of financial performance. As you saw in yesterday's press release, we issued 2025 financial guidance, including revenues of $6,200,000,000 to $6,450,000,000 and adjusted EBITDA of $575,000,000 to $615,000,000 At the guidance midpoint, that represents 2025 revenue growth of 6% and adjusted EBITDA growth of 19%. Embedded in our 2025 outlook is an adjusted EBITDA midpoint of 13.6%, which implies 110 basis points of margin expansion, driven largely by the expected annualization of new state PPP programs to begin in 2024. We are targeting an additional 100 to 200 basis points of margin improvement over the next three to four years. That would put us solidly in our target mid teens adjusted EBITDAR margin range.

[Marty Bonick, CEO at Ardent Health Partners]

As we begin 2025, we are encouraged by early volume trends. All signs continue to point to demand remaining durable, although we continue to face some industry headwinds, including ongoing subsidy pressure for hospital based physician services and elevated payer denials. However, more than offsetting these headwinds are the tailwinds of underlying volume growth, above historical average commercial rate increases, incremental DPP contributions and core operating initiatives that will drive margin expansion and set Arden up for strong EBITDA growth of 19% at our guidance midpoint. We certainly recognize there continues to be a level of legislative uncertainty for the broader healthcare industry, including providers. As everyone knows, a number of potential changes are being discussed in the headlines, but we continue to believe that changes will ultimately be incremental in nature and we believe we are relatively insulated against many of these risks on several fronts.

[Marty Bonick, CEO at Ardent Health Partners]

First, our 2024 exchange payer base contributed only 3.6% of total revenues in 2024, and we believe only a fraction of this volume would be at risk if the enhanced subsidies were not extended in 2026. Second, broadly speaking, we would likely have more limited exposure to site neutrality proposals given our relatively smaller ambulatory footprint. And third, we naturally don't have exposure to 340B drug pricing if there were changes on that front. We, of course, continue to monitor potential regulatory changes and advocate with our elected officials to continue to support policies that protect access to coverage and care. In the meantime, our team remains dedicated to executing day in and day out on our strategic plans and financial objectives.

[Marty Bonick, CEO at Ardent Health Partners]

To augment that mission, we are currently recruiting for and plan to hire a Chief Operating Officer later in this year. This addition to our executive management team will further complement our existing executive team and help drive our operational excellence initiatives and deliver on our commitments, including our M and A initiatives. We believe that augmenting the executive team with another key hire will support our efforts to help Arden maximize its potential. With that, I will now hand the call over to Alfred.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Thanks, Marty, and good morning to everyone on the call with us today. As Marty indicated, we had a very strong finish to the year and are looking to sustain our operating momentum into 2025. Our significant growth in 2024 is a reflection of strong underlying operating performance, execution of our core margin improvement initiatives and Medicaid DPP programs beginning in Oklahoma and New Mexico. CMS's retroactive approval of the New Mexico DPP program in November for the period covering 07/01/2024 through 12/31/2024, was an important milestone for the state and is the culmination of hard work from the legislature and the healthcare community. As a reminder, the $94,000,000 revenue and $65,000,000 EBITDA benefit Marty mentioned earlier are associated with the financial impact for the full second half of twenty twenty four.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

On a reported basis, we delivered financial results well above our full year guidance. 2024 revenue of $5,970,000,000 was roughly $90,000,000 above the top end of our guidance and adjusted EBITDA of $498,000,000 was nearly $60,000,000 above the top end of our range. Even when we exclude the New Mexico DPP benefit that wasn't in our 2024 guidance, Ardent delivered strong results to finish the year. Excluding the New Mexico DPP impact, full year 2024 revenue was $5,870,000,000 near the top end of our $5,800,000,000 to $5,875,000,000 guidance range. 2024 adjusted EBITDA was $433,500,000 or $1,000,000 above our guidance midpoint.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

2024 net patient service revenue per adjusted admission grew 3.4%, slightly above the top end of our 2.6% to 3.3% guidance range. And 2024 adjusted admissions grew 4.8%, again above the midpoint of our guidance range of 4.5%

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

to

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

5%. In terms of the fourth quarter of twenty twenty four, year over year growth rates are higher due to the New Mexico DBP benefit as well as the cybersecurity incident that took place in the fourth quarter of twenty twenty three. That said, on a reported basis, total revenue for the quarter was $1,600,000,000 an increase of 19% compared to the fourth quarter of twenty twenty three. Adjusted Adjusted EBITDA for the quarter grew 213% compared to the prior year to $183,000,000 For the full year 2024, reported revenue increased 10% year over year and adjusted EBITDA grew 58%. Our adjusted EBITDAR margin for 2024 expanded two forty basis points from 10.1% in 2023 to 12.5%, advancing materially towards our long term target of mid teens adjusted EBITDAR margins.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

In terms of revenue mix, 2024 Medicaid declined 90 basis points year over year to 10.3%. This decline largely reflects the impact of Medicaid redeterminations. On the flip side, our commercial mix increased 100 basis points year over year to 43.6%, driven primarily by growth in exchange volumes. As Marty mentioned earlier, our exchange revenue contribution is still a modest 3.6% of total 2024 revenue. In terms of reported volumes, fourth quarter admissions of approximately 40,000 represented an increase of 11.5% over the prior year.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Growth in general medicine, cardiology and neurology were particularly strong. For the fourth quarter of twenty twenty four, adjusted admissions grew 9% year over year. Total surgeries increased 6.3% year over year, reflecting inpatient and outpatient surgery growth of 8.75.4% respectively. And ER visits in the fourth quarter grew 6.7% year over year. Contract labor expense represented 3.6% of total salaries and benefits for the fourth quarter of twenty twenty four compared to 4.3% to the comparable quarter a year ago.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

We continue to see contract labor utilization and rates normalize across our markets as well as improvements in our nursing retention rates. Moving on to cash flow and liquidity, we ended the fourth quarter with total cash of $557,000,000 and total debt outstanding of $1,100,000,000 Our total cash and available liquidity at the end of the fourth quarter was $845,000,000 Cash provided by operating activities during the fourth quarter was $120,000,000 compared to $67,000,000 for the fourth quarter of twenty twenty three. Capital expenditures during the fourth quarter were $81,000,000 up from a quarterly average of $35,000,000 for the first three quarters of twenty twenty four. This step up in capital spending was largely anticipated in our 2024 guidance. We finished the year with $188,000,000 of CapEx spend just above the top end of our guidance range as we opportunistically took advantage of buying out some surgical robot leases.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

At year end, our total net leverage as calculated under our credit agreement was 1.2 times and our lease adjusted net leverage was 2.9 times, down from 3.5 times at the end of the third quarter. So as we turn to 2025, we remain focused on delivering value to our patients and shareholders. While it's early in the year, we're encouraged by our volume trends and that gives us increased confidence in the durability of the demand we're seeing. In yesterday's earnings release, we provided initial 2025 guidance that at the midpoint implies revenue and adjusted EBITDA growth of 619% respectively. Additionally, the midpoint of our guidance implies 2025 EBITDAR margin expansion of 110 basis points to 13.6%.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Embedded in our 2025 outlook is a year over year increase of approximately $75,000,000 in EBITDA from DPP programs. This increase primarily reflects the expected full year impact from the New Mexico and Oklahoma DPP programs. This is consistent with our previously communicated expectations for growth in DPP programs in 2025 over 2024. The only mechanical nuance is the $65,000,000 we recorded in 2024 from the retroactive approval of the New Mexico DPP program was not in our 2024 guidance. So now the twenty twenty five year over year EBITDA increase attributable to DPP programs is expected to be $75,000,000 versus the $140,000,000 that we've previously discussed.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

A complete list of our guidance metrics is provided in our earnings release, but some key highlights include total revenue of between $6,200,000,000 and $6,450,000,000 net income attributable to Ardent Health of $245,000,000 to $285,000,000 implying full year diluted EPS of between $1.73 and $2.01 adjusted EBITDA of $575,000,000 to $615,000,000 total adjusted admissions growth of between 23% net patient service revenue per adjusted admission growth of 2.1 to 4.4% and we expect capital expenditures of between $215,000,000 to $235,000,000 or 3.6% of revenue at the midpoint. As a reminder, this increase is consistent with our previous comments that CapEx would likely approach 4% of revenue over time. While we aren't going to be providing specific quarterly guidance, we did want to comment on earnings seasonality. At a high level, we would typically expect the second and fourth quarters to be our highest EBITDA contributors to our full year results and the first and third quarters to be our lowest. This year, the timing of CMS approval of the 2025 New Mexico DPP program renewal could potentially alter quarterly earnings recognition.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

New Mexico submitted a renewal application in December 2024. Given the ongoing transition to the new administration, it's possible the 2025 program won't be renewed by the end of the first quarter. In that scenario, we would not record any New Mexico DPP revenue in the first quarter and instead would have cumulative revenue recognition of 2025 program amounts in the quarter that CMS approval is received. This would not affect the annual contribution, but is a factor to consider in quarterly modeling. So with that, I'd like to turn the call back to Marty for a few final comments on

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

the quarter before we open the call to questions. Marty?

[Marty Bonick, CEO at Ardent Health Partners]

Thank you, Alfred. In summary, we continue to make substantial progress as we execute on our key strategic initiatives and leverage the consumer focused platform we have built to create long term shareholder value. We are pleased with our strong finish to 2024, delivering attractive financial and operating performance for the year.

[Marty Bonick, CEO at Ardent Health Partners]

We continue to advance our focus on market share growth, taking a disciplined approach to evaluating opportunities in both the ambulatory space as well as acute care hospitals. Our NextCare acquisition squarely fits into this. And with leverage below 3x and ample cash, we will continue to assess opportunities to execute on this strategy. Finally, we are encouraged by volume trends to start the year and are focused on sustainable growth in 2025 and beyond. I want to close by thanking our 24,000 team members and more than 1,800 employed and affiliated providers who continue to deliver exceptional care to patients across the communities we serve.

[Marty Bonick, CEO at Ardent Health Partners]

Together, we are focused on making healthcare better and fulfilling our purpose of caring for our patients, our communities, and one another. With that, operator, please open the line for questions.

[Operator]

Thank you. We will now begin the question and answer session. We'll take our first question from Whit Mayo at Leerink Partners.

[Whit Mayo, Senior Managing Director at Leerink Partners]

Hey, maybe just to follow-up, Alfred, on that last point on New Mexico, just to make sure I get this correct. So you need approval from CMS. So we should do we just take the '65, divide that by four and say take that out of first quarter and apply it to a different quarter? Is that basically the math to do?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Hey, Whit. This is Alfred. Yes, you've got it generally correct now. The '65 is the year over year increase attributable to New Mexico. And of course, we booked the 65 and they'll representing the last half of the year.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

So when you think about quarterly amounts, yes, it's not wrong to think about that total quantum divided by four.

[Whit Mayo, Senior Managing Director at Leerink Partners]

Okay. And then my follow-up is just, I mean, the volume certainly stand out as being fairly robust versus what we've seen reported from the peer group. I was just hoping maybe you could unpack this just a little bit more just how broad based it was across the portfolio, any one market materially outperforming others? And then you referenced in your prepared comments that the demand or volume environment continues to remain strong. Guidance this year is 2% to 3% on adjusted admissions, which feels more normal.

[Whit Mayo, Senior Managing Director at Leerink Partners]

Maybe this is just some conservatism here, but maybe it's just to put some of that into context. Thanks.

[Marty Bonick, CEO at Ardent Health Partners]

This is Marty. I'll start and then turn it back to Alfred. But, yes, to the question about volumes and durability, we continue to believe in the strength of the positions we have in our markets and our markets are continuing to grow.

[Marty Bonick, CEO at Ardent Health Partners]

This is not a one off in one market or another. We see it's pretty consistent across the portfolio. And we're encouraged by, again, as Alput said, the early signs of volume demand in the first part of this year as well. So nothing to call out specifically, just to get continued strength and strong positions in our markets and growing markets, and continuing to operationalize through our transfer centers and through our internal efficiencies, how we'll be able to take more transfers into the system and service more demand for our patients.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. Just tailgating on Marty's comments with, yeah, as you saw in our release, you know, year over year, adjusted admissions increased, you know, for 2024, you know, almost 5% at at 4.8%. Now clearly, 2024 benefited from two midnight rule. You know, we put that year, full year increase in the, you know, think of that as maybe a 40, hundred and 50 basis points of that increase. So stripping that out, you know, we were just north of 3%, you know, call it 3.2, three point three percent.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

And as you saw in our guidance today, you know, we have a range of two to 3%. And, yeah, so maybe perhaps a tad bit of conservatism in that range. And to Marty's point, you know, we think, you know, we've all heard the kind of the strength of the respiratory season. And, yeah, we feel,

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

you know,

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

we we feel very good about the, you know, continuing the same trend given the strong markets we're in, that we'll continue to see growth.

[Whit Mayo, Senior Managing Director at Leerink Partners]

Thanks.

[Operator]

We'll move to our next question from Anne Hynes at Mizuho Securities.

[Ann Hynes, Senior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group]

Great. Thank you. Good morning.

[Ann Hynes, Senior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group]

I know at a recent conference you highlighted physician expense was a little bit more pressure than you expected. Can you just provide an update on how that is trending? And then in your prepared remarks, you talked about over the next three to four years ex the DPP program, you have a path to 100 to 200 basis point of baseline margin improvement. Can you remind us what the drivers of that margin improvement is? And within that, what do you expect like an annual growth rate is for this physician expense?

[Ann Hynes, Senior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group]

Thanks.

[Marty Bonick, CEO at Ardent Health Partners]

Good morning, Anne. This is Marty. I'll start and then let Alfred take the second part of your question. On the physician expenses, we did see, the hospital based physician subsidies moderate from '23 to '24. And from '24 to '25, we expect it to be somewhere in that similar range.

[Marty Bonick, CEO at Ardent Health Partners]

It has come down from the peak in 'twenty three, but it's still running slightly above inflation from what we would have otherwise expected. We are seeing good movement with our renegotiations. We substantially renegotiated our ER and anesthesia contracts during that 'twenty '3 and early 'twenty four period. We've seen some modest pressure from radiology, but radiology is also a smaller portion of those total subsidies. So, we're continuing to monitor that.

[Marty Bonick, CEO at Ardent Health Partners]

Our operational teams are working diligently with our different vendor partners in each of our markets and some of our local providers to offset some of those headwinds. And,

[Marty Bonick, CEO at Ardent Health Partners]

we expect

[Marty Bonick, CEO at Ardent Health Partners]

this to continue to moderate as we go through the year.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. Anne, this is Alfred. I'll touch on the second part of your question, which is the margin improvement initiatives over the next three to four years you know, attributing to the, improvement in our overall margins. You know, we would put that into, you know, a number of different buckets.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

And as you can imagine, just given the profile of our, P and L, a healthy dose of that comes in the form of both labor initiatives, as well as supply chain initiatives. And that can include, you know, a number of overhead initiatives continuing to get leverage off of our, G and A expense and continuing to focus on our service line optimization as well as, improvements from technology enhancements. So, you know, I would say it's a whole litany of efforts and initiatives that, we have plans over the near end, intermediate term.

[Operator]

Great. Thank you. We'll take our next question from Scott Fidel at Stephens.

[Scott Fidel, Managing Director at Stephens Inc]

Hi. Thanks. Good morning. First question, just would appreciate if you can give us an update into just how the JD pipeline and conversations are developing or sort of in flight here early in 2025. And then we'd be curious just around how you think about the effects on the JV discussions just from the legislative funding reform talks in Washington.

[Scott Fidel, Managing Director at Stephens Inc]

Curious whether that's something you would see as a potential accelerant to that as potential partners may be looking to another partner to help optimize performance against the backdrop of maybe some more funding pressure? Or is it just sort of providing a near term chilling effect just as partners may want to see how ultimately, the, I guess, the legislative sauce is making it sort of playing out in Washington?

[Marty Bonick, CEO at Ardent Health Partners]

Hey, Scott. Thanks for the question. This is Marty. Our JV pipeline, I'd say our acquisition pipeline in general, both on the outpatient and the inpatient continues to build. We're encouraged by the progress they're seeing and the conversations that we're having.

[Marty Bonick, CEO at Ardent Health Partners]

While we don't have anything to report right now, we are continuing to be encouraged about our growth trajectory that we've previously spoken about. And we see that JV partnership as an important part of that strategy as we go forward. The effects from potential changes in Washington on JV partners, I would say that there's definitely concern, particularly those academic institutions that are more heavily dependent upon NIH funding and research. I think that that will put pressure on their plans and I think that that will ultimately benefit us as we look towards new expansion opportunities. Certainly the conversations, as I said, have been robust and continuing to build, but not seeing any direct impact yet is what you alluded to.

[Marty Bonick, CEO at Ardent Health Partners]

I think people are still trying to understand the magnitude of what these changes might be and there's still a lot of uncertainty out there. There's been a lot of discussion but not a lot of details coming out of some of those. So in summary, we continue to be optimistic about the pipeline that we have for growth and think that some of these changes will ultimately provide a modest tailwind to our growth initiatives.

[Scott Fidel, Managing Director at Stephens Inc]

Okay. And then just my follow-up question. If maybe you could sort of give us your projections for operating cash flow for 2025. And then relative to I guess both cash flows and then the CapEx guidance you provided, any call outs you'd want to give around sort of from a modeling perspective, any seasonal considerations that we should be thinking about separate from the Mexico PPP, just anything else offered, for seasonally from either cash flow or the timing of the CapEx that you think we should be considering when we model that? Thank you.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yes. Thanks, Scott. Yeah. In terms of seasonal considerations on CapEx, I wouldn't, you know, this year we had a pretty significant skew towards Q4 as you saw in our Q4 numbers. Now some of that was, as I mentioned, the, we had a real good opportunity to buy out some CapEx leases so that skewed it even more.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

I think there still is a tendency for our CapEx to be a little bit back half loaded so I wouldn't hesitate to skew it, but certainly not to the extent that we saw from a from a back end in 2024. But, and you are, of course, seeing a step up in our CapEx spend as consistent with our expectations for ambulatory investments that we're making and that's embedded inside of our guidance. In terms of, you know, we haven't provided formal guidance for operating cash flow, for the year. You know, we could see that being in the upper $400,000,000 range in terms of a very broad based estimate.

[Scott Fidel, Managing Director at Stephens Inc]

Okay. Thank you.

[Operator]

We'll move next to Ben Hendricks at RBC Capital Markets.

[Ben Hendrix, Vice President at RBC Capital Markets]

Great. Thank you very much. I wanted to follow-up on the professional fee, and subsidy commentary. I was wondering if you could quantify how much more professional fee expense you're including in twenty twenty five guidance versus levels you may have been contemplating like two quarters ago, late twenty twenty four timeframe?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. This is Alfred Ben. You know, I would say, you know, our perspective obviously and our commentary that we made at JP Morgan in January, you know, is consistent with our expectations, you know, that it will continue to be a headwind. It will continue to grow as a percent of revenue on a year over year basis. We think '25, that growth in 'twenty five is actually going to look a lot like the growth in 'twenty four.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Certainly nothing like we saw in 'twenty three where we consumed over 100 basis points of margins from that step up. But we're seeing headwind in 2025 that will look similar to what we saw in 2024.

[Ben Hendrix, Vice President at RBC Capital Markets]

Great. And then just separately, appreciate all the commentary about the acquisitions, the 18 urgent care clinics. Could you just maybe talk about what you're seeing in terms of the pipeline across your markets in terms of both urgent care and ambulatory tuck ins? Thanks.

[Marty Bonick, CEO at Ardent Health Partners]

Hey, Ben. It's Marty. Yeah, we see continued opportunities for expansion in our markets. Again, we've had historically a lesser percentage of outpatient services maybe relative to our peer group. And we know in our markets, given the growth in those markets, that there's opportunities to expand both in the hospital and beyond the hospital.

[Marty Bonick, CEO at Ardent Health Partners]

And so urgent cares was that early focus that we set out when we went public last year and we've made good progress on those commitments. We see continued opportunities for expansion of urgent cares, both perhaps from an M and A perspective, but also from a de novo as we continue to round out pockets of geographies where we don't have representation. But we're also going to be turning our focus this year into other ambulatory assets, looking at ambulatory surgery centers, perhaps imaging centers, freestanding EDs and the like. So this is just a continued expansion of what we set out to do and we still see good demand for services growth across our markets.

[Operator]

We'll go next to Joanna Gajuk at Bank of America.

[Joanna Gajuk, Equity Research Analyst at Bank of America]

Hi, good morning. Thanks so much for taking the question. So I guess first a couple of clarifications. So Q4 volumes, right, these metrics are essentially skewed because there was easy comp a year ago, right? There was the cybersecurity event, right?

[Marty Bonick, CEO at Ardent Health Partners]

That's correct, Ann. That's Marty.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah.

[Joanna Gajuk, Equity Research Analyst at Bank of America]

Okay. And then because the I'm sorry. Go ahead.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

No. You're exactly right. This is Alfred. The the cybersecurity incident started on Thanksgiving last year and, certainly had an impact through the end of the year from an overall volume perspective. So we say it was an easy comp.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

But clearly, our volumes were impacted by the outage.

[Joanna Gajuk, Equity Research Analyst at Bank of America]

And what would you say, is there a way to think about a full year benefit that you saw in 2024 because of that easy comp? I mean, I guess, on the flip side, it's probably some headwind that you had in early Q1 twenty twenty four, right, because it was continuing a little bit there. Just thinking about your volume up to 2025, so there's a two midnight room that the benefit will not repeat. And I'm trying to think you know, the two to three versus three, like is there also a reason, you know, because of this dynamic year over year '24 maybe had an easier comp.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. This is Alfred. You know, I would say, you know, we've been pretty clear that the cyber event was largely behind us as we turned, the calendar into January. So I don't think, from a '24 to '25, it's really embedded in the, in in the volumes. You know, we have said, from a two midnight rule, you know, again, from a full year basis, that is maybe a 40 basis points of our adjusted admin growth, you know, which again, for full year '24 was 4.8%.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

So, you know, with without the two midnight, we think it would have, you know, ballpark been in the, you know, mid threes, you know, call it 3.3, three point four. So but again, I would say, you know, when you think about the cyber event, the twenty four to twenty five, comparisons are gonna be really clean.

[Joanna Gajuk, Equity Research Analyst at Bank of America]

Right. And you had mentioned a Q1 trend so far where you're seeing an uplift. So is this really the flu season or the risk for the cases kind of higher year over year?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yes. Clearly, as Marty indicated, we feel good about how the year started from a volume. We've all heard about the strength of the flu season. Now, you know, again, those are those certainly provide volume admissions, but of course, those are much lower acuity overall. And, you know, again, it goes to, you know, our overall strategy in terms of growing our ambulatory footprint, being able to see the right, patient in the right setting.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

But, yeah. So clearly from an admissions perspective, we would expect that neoplu will have some modest impact to, '25 because this does appear to be, you know, a, you know, from a multiyear standpoint, a stronger, not just flu, but other respiratory illnesses. But again, I would consider those to be generally much lower acuity and not driving a material financial benefit.

[Joanna Gajuk, Equity Research Analyst at Bank of America]

Okay. Thank you. And if I may last follow-up on a comment, I appreciate when you know your comments around these potential I guess proposals are being discussed in Congress as you don't think it would be material for the company and you made some really comment about fact neutral funds. So I just want to follow-up on that because I guess there's a branch of things right that's being considered when we say that neutral, you know, there's other physician admission drugs. So that will be, you know, not that material.

[Joanna Gajuk, Equity Research Analyst at Bank of America]

But I guess the other end of the spectrum is, you know, kind of changing the reimbursement for some of the surgeries, right, and paying them at the lower level of AC level. So if that was to happen, like how would you think about trying to kind of quantify the impact of that type of site neutral reform for your company? Thank you.

[Marty Bonick, CEO at Ardent Health Partners]

Yes. Joanna, this is Marty. Again, to your point, there's not been any clear communication on if or what changes might occur related to site neutral. There's certainly been a lot lot of chatter. As we stated before, our exposure to the freestanding site neutral services are much more limited given our smaller footprint.

[Marty Bonick, CEO at Ardent Health Partners]

It's an area we're growing into, but it's not an area that we have a big exposure on today. So, as we look at that, we expect that that's impact. There's a report of 66 APCs that has been floated out there. If that were to come to pass, I think that that's a stretch to say that it would all happen. Our quantification is somewhere less than $10,000,000 impact.

[Joanna Gajuk, Equity Research Analyst at Bank of America]

Great. Thank you.

[Operator]

Our next question comes from Craig Hettenbach at Morgan Stanley.

[Craig Hettenbach, Executive Director at Morgan Stanley]

Yes. Thank you. And nice to see the New Mexico DPP come through. Can you just talk about just the visibility and durability of those, programs as you see it for this year and beyond?

[Marty Bonick, CEO at Ardent Health Partners]

Yeah. Craig, this is Marty. Thanks for the question. We were excited to see that. Our teams did a lot of work to, to help make sure that that happened and we can get additional reimbursement for caring for that population across New Mexico.

[Marty Bonick, CEO at Ardent Health Partners]

It's really helpful for us and all providers across the state. Given that this program was approved, if we look back historically, these programs started back in 2016 and there's not been a program that we're aware of that once it's been approved, it's not been reapproved. And so we consider this in the approved category. And, while we understand that CMS has been sort of on a restricted communications protocol without waiting for the confirmation of a CMS administrator, we do expect that these programs will continue to move forward. They are important not only to companies like us, but again, providers all across the state.

[Marty Bonick, CEO at Ardent Health Partners]

And this is really just helping to defray some of the costs that have not been historically covered by Medicaid in providing for those patient populations. And so we still see these as very durable, very necessary and important to the safety net of states across the country. And as recently as yesterday, President Trump in his first cabinet meeting again reaffirmed that he was not going after Medicare, Medicaid programs, that they'd be targeting fraud and abuse. And so, all of that is continued indications that we expect these programs to remain durable into the future.

[Craig Hettenbach, Executive Director at Morgan Stanley]

Got it. And then

[Craig Hettenbach, Executive Director at Morgan Stanley]

just a follow-up on commentary around acuity. Outside of just kind of flu season, anything else you would call out in terms of just underlying trends you're seeing across the business from an acuity perspective?

[Marty Bonick, CEO at Ardent Health Partners]

This is Marty and I'll let Alfred chime in here. But acuity continues to be strong. Again, we think that that's largely part because of our focus around, our service line optimization initiatives, capacity initiatives, and our transfer center initiatives is just making sure that we can care for those acute cases that have need and services while caring for lower acuity patients in our outpatient settings or clinics. And so, Alfred, could you talk a little bit more about the specifics?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. The only thing I would add, Greg, is, you know, clearly the two midnight rule in 2024 did have an acuity impact because you, you know, you did see these lower acuity admissions, move from ops. And so overall, you know, our CMI nudged down a little bit as a consequence of those two. But of course, you know, we lap that in 'twenty five. So, yeah, we would continue to expect to see, you know, acuity consistent with, with 2024.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

And again, going to our expectations for growing our ambulatory footprint, continuing to see focus on seeing the right patient in the right setting, we think overall, you know, that should have a longer term benefit on our CMI.

[Operator]

We'll go next to Matthew Gilmore at KeyBanc.

[Matthew Gillmor, Director & Senior Research Aanalyst at KeyBanc Capital Markets]

Hey, thanks for the question. I wanted to ask about the length of stay metric. You've done a good job driving that lower in 2024. Maybe there's some influence with the two midnight dynamic that Alfred just mentioned. Marty had talked about the device you've been rolling out to collect vitals and improve nurse rounding.

[Matthew Gillmor, Director & Senior Research Aanalyst at KeyBanc Capital Markets]

I was curious how that, rollout has been progressing as it having a discernible impact on like the say at this point?

[Marty Bonick, CEO at Ardent Health Partners]

Hey, Matt. This is Marty. Thanks for that question. Yes. I think you're right.

[Marty Bonick, CEO at Ardent Health Partners]

In the beginning, the length of stay with the impact of the two midnight that they offered to quantify before certainly had some portion. But again, our efficiency metrics and our focus around efficiency across the platform has been, additional to that. The device that you mentioned, the BioButton, we have continued to see rollout. I don't have the exact statistic in front of me in terms of the number of facilities and beds that it's in right now. But we continue to see good progress both from a clinical outcomes perspective and reduction of mortality rates for patients that have that device as well as a length of stay impact that has been, additive to the other operational efficiencies that we've been focusing on.

[Marty Bonick, CEO at Ardent Health Partners]

And so it's difficult to segment out how much is attributable to the device versus other things. But collectively, it has been an impact that we expect to continue to expand throughout the system.

[Matthew Gillmor, Director & Senior Research Aanalyst at KeyBanc Capital Markets]

That's great. And then just a quick follow-up probably for Alfred just on the mechanics of the accounting for the New Mexico, DPP for 25 portion. Does that need to get approved by March 31 for you to pull it into the first quarter or even if the approval comes, say, in mid April, you'd still be able to recognize that, for the first quarter.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Thanks, Matt. No. I appreciate, that clarification. Yes. We would expect that the accounting would follow the approval date so that if the approval came after the March that, that would push recognition, cumulatively to whatever quarter it was approved.

[Matthew Gillmor, Director & Senior Research Aanalyst at KeyBanc Capital Markets]

Got it. Thanks very much.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Thank you.

[Operator]

And next we'll move to Benjamin Rossi at JPMorgan.

[Benjamin Rossi, Equity Research Associate at JP Morgan]

Hey, thanks for the question. So just following up on acuity here on the you've seen a pretty sizable delta for your 2025 net patient service revenue per adjusted admissions growth range. Can you just walk us through puts and takes being contemplated across your pricing mix and maybe what brings you closer to the upper end or lower end here?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah, sure. I'll start. Obviously, the range is influenced. It's mostly kind of a back end calculation based off of the range of revenue and adjusted admits. I'll comment on what we're saying from a commercial rate perspective.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

You know, we continue to see renewals above, you know, what I would call historical ranges, in the 3% kind of range. You know, we've been, well over 4% from our most recent renewals. And so, you know, we continue to expect, you know, and push for as a consequence of the types of inflation. You know, we've talked ad nauseam about the impact of professional fees on our business. And so, you know, I would say, you know, we're continuing to, you know, it's not an easy payer environment as you might guess, but we've continued to be successful into getting the type of reimbursement increases that we need, given the underlying cost inflation in our business.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

That's really what I would comment on that, you know, again, that range is kind of necessarily why just given the dynamics of the width of the revenue range.

[Benjamin Rossi, Equity Research Associate at JP Morgan]

That makes sense. So this is a follow-up then on the ACA sign ups. I know you mentioned that exchange is about 3.6% of revenue, but just looking at the initial sign ups in like the low double digit range in a market like Texas, how are you thinking about contribution from the exchanges to your 2025 volume growth expectations?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. This is Alfred. You know, again, while those growth rates are impressive and I think our markets are probably slightly north of the averages overall given, you know, our relatively small compared to our peer set, exposure to those exchange volumes. It's still a relatively small, you know, even though it's a large increase on a small base, it's still a small number overall. So it's I would say it's not meaningful to call out from an overall growth perspective.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

And as we think about, you know, obviously there's been a lot of speculation around, you know, Hicks exposure post 2025 with the expiration of the subsidies. It is still our perspective that those lives will go somewhere if, again, assuming the I'll say the worst happens and those subsidies and and nothing comes in place of those subsidies, we still feel strongly that it would likely, attract to not maybe not a dissimilar experience to Medicaid redeterminations where those lives end up going somewhere and that it's not necessarily a bad scenario. But again, just given our overall small exposure, Again, I would say we're not, we don't, as you look at our overall growth, that's still a very small component of it.

[Marty Bonick, CEO at Ardent Health Partners]

Yeah, I'll just add on to that, Ben, that coverage is good. And I think that that is what is going to be necessary. And I think as Congress weighs how it deals with healthcare issues, the strength of the ACA, even though it's a smaller percentage for us, is very necessary part of, again, the healthcare fabric. And so we continue to advocate for those programs to be there so that patients don't lose coverage, you know, across our footprint or anywhere else across the country.

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. And the this is Alfred. The last thing I would add is that the overall revenue contribution and margin contribution from those HICs lives is gonna be closer to, a Medicare rate than it is actually a traditional commercial rate.

[Benjamin Rossi, Equity Research Associate at JP Morgan]

Got it. Thanks for that, clarification. Is it fair to say then that there's maybe a a 10% to 15% kind of discount then from like your Medicare or traditional commercial just to kind of bridge that ACA sort of reimbursement dynamic?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

I want to be sure I follow your question. I'm not sure I captured it.

[Benjamin Rossi, Equity Research Associate at JP Morgan]

Just trying to think of a discount. And you mentioned that the ACA exchange plans kinda come in line more with your Medicare. Just curious on, how those, how that kinda compares to your broader commercial book?

[Alfred Lumsdaine, Chief Financial Officer at Ardent Health Partners]

Yeah. I I guess I might answer the question this way. When I think about, a Hicks life from a reimbursement perspective and a Medicare life and a true commercial life, I would, you know, if I was just gonna give broad justice, I would say the reimbursement is, you know, if I took that quantum of difference between Medicare and commercial, it's maybe about a third of the way towards a commercial rate.

[Benjamin Rossi, Equity Research Associate at JP Morgan]

Great. Thanks for the color there. Appreciate it.

[Operator]

And with that, today's conference call is concluded. Thank you for your participation. You may now disconnect.

Participants

Executives

• David Styblo, SVP - Investor Relations
• Marty Bonick, CEO
• Alfred Lumsdaine, Chief Financial Officer

Analysts

• Whit Mayo, Senior Managing Director at Leerink Partners
• Ann Hynes, Senior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group
• Scott Fidel, Managing Director at Stephens Inc
• Ben Hendrix, Vice President at RBC Capital Markets
• Joanna Gajuk, Equity Research Analyst at Bank of America
• Craig Hettenbach, Executive Director at Morgan Stanley
• Matthew Gillmor, Director & Senior Research Aanalyst at KeyBanc Capital Markets
• Benjamin Rossi, Equity Research Associate at JP Morgan